医学
前列腺癌
生活质量(医疗保健)
疾病
阶段(地层学)
阉割
疾病管理
重症监护医学
癌症
妇科
内科学
护理部
激素
古生物学
帕金森病
生物
出处
期刊:PubMed
日期:2024-03-22
卷期号:46: 33-43
标识
DOI:10.3760/cma.j.cn112152-20240206-00067
摘要
With the advancement of prostate cancer (PCa) diagnosis and treatment technology, the 5-year survival rate has remarkably increased, and PCa has entered the era of chronic disease management. Medical castration therapy remains the cornerstone treatment option for PCa patients, and run throughout the various stages of patient treatment. The disease progression, treatment-related adverse reactions and related complications of PCa patients after medical castration have become a major problem in the long-term management of PCa patients, affecting the survival and quality of life of patients. In addition to focus on the disease management of prostate patients during diagnosis and treatment, patients should be closely followed up after medical castration, especially for those at the critical stage of disease treatment. Testosterone or other indicators should be monitored at important nodes of the disease (the point of initiation disease phase and the point of treatment switch) to avoid missing the optimal treatment window. Follow-up management of PCa should take into account the characteristics of the treatment stage of the disease (disease stage, previous symptoms, prognostic factors and treatment strategy) and patients' own demands, and personalized follow-up strategies should be recommended to better increase patients' treatment compliance and improve patients' prognosis. Currently, there is a lack of guidelines or consensus on the management on the follow-up and quality of life of PCa patients after medical castration in China. Therefore, the Chinese Prostate Cancer Consortium has organized domestic experts to formulate this consensus, with the aim of providing a reference for the management on the follow-up and quality of life of PCa patients receiving medical castration therapy, and to further improve the prognosis and quality of life of PCa patients in China.随着诊疗技术的进步,前列腺癌患者的5年生存率显著提升,前列腺癌进入慢性疾病管理时代。雄激素剥夺治疗是晚期前列腺癌患者的基石治疗方案,并贯穿患者治疗的各阶段。前列腺癌药物去势治疗后的疾病进展、治疗相关不良反应以及相关并发症已成为前列腺癌患者长期管理的一大难题,影响患者的生存及生活质量。除了在诊断和治疗过程中需要注重前列腺癌患者的疾病管理,更应该密切随访药物去势治疗后患者的整体情况,尤其处于疾病治疗关键阶段的患者,应在疾病重要节点(疾病阶段起始点和治疗切换点)监测睾酮或其他指标,避免错过最佳治疗窗口期。前列腺癌随访管理应该兼顾疾病本身治疗阶段特点(疾病分期、既往症状、预后因素及治疗方案)和患者自身诉求,定制个性化的随访策略,更好地提高患者治疗依从性,改善患者预后。目前中国尚缺乏前列腺癌患者药物去势治疗后随访及生活质量管理的指南或共识,为此中国前列腺癌研究协作组委员会组织国内相关专家制定了前列腺癌药物去势治疗随访管理中国专家共识(2024版),以期为接受药物去势治疗前列腺癌患者的随访及生活管理提供参考,进一步改善中国前列腺癌患者的预后及生活质量。.
科研通智能强力驱动
Strongly Powered by AbleSci AI